Rotundo R F, Vincent P A, McKeown-Longo P J, Blumenstock F A, Saba T M
Department of Physiology and Cell Biology, Albany Medical College, Albany, New York 12208, USA.
Am J Physiol. 1999 Dec;277(6):G1189-99. doi: 10.1152/ajpgi.1999.277.6.G1189.
Fibronectin (Fn) is a major adhesive protein found in the hepatic extracellular matrix (ECM). In adult rats, the in vivo turnover of plasma Fn (pFn) incorporated into the liver ECM is relatively rapid, i.e., <24 h, but the regulation of its turnover has not been defined. We previously reported that cellular Fn (cFn) and enzymatically desialylated plasma Fn (aFn), both of which have a high density of exposed terminal galactose residues, rapidly interact with hepatic asialoglycoprotein receptors (ASGP-R) in association with their plasma clearance after intravenous infusion. With the use of adult male rats (250-350 g) and measurement of the deoxycholate (DOC)-insoluble (125)I-labeled Fn in the liver, we determined whether the ASGP-R system can also influence the hepatic matrix retention of various forms of Fn. There was a rapid deposition of (125)I-pFn, (125)I-aFn, and (125)I-cFn into the liver ECM after their intravenous injection. Although (125)I-pFn was slowly lost from the liver matrix over 24 h, more than 90% of the incorporated (125)I-aFn and (125)I-cFn was cleared within 4 h (P < 0.01). Intravenous infusion of excess nonlabeled asialofetuin to competitively inhibit the hepatic ASGP-R delayed the rapid turnover of both aFn and cFn already incorporated within the ECM of the liver. ECM retention of both (125)I-aFn and (125)I-cFn was also less than (125)I-pFn (P < 0.01) as determined in vitro using liver slices preloaded in vivo with either tracer form of Fn. The hepatic ASGP-R appears to participate in the turnover of aFn and cFn within the liver ECM, whereas a non-ASGP-R-associated endocytic pathway apparently influences the removal of normal pFn incorporated within the hepatic ECM, unless it becomes locally desialylated.
纤连蛋白(Fn)是一种存在于肝脏细胞外基质(ECM)中的主要黏附蛋白。在成年大鼠中,整合到肝脏ECM中的血浆Fn(pFn)在体内的周转相对较快,即<24小时,但其周转的调节尚未明确。我们之前报道过,细胞Fn(cFn)和经酶法去唾液酸化的血浆Fn(aFn),两者都有高密度暴露的末端半乳糖残基,在静脉注射后与血浆清除相关联,它们会迅速与肝脏去唾液酸糖蛋白受体(ASGP-R)相互作用。使用成年雄性大鼠(250 - 350克)并测量肝脏中脱氧胆酸盐(DOC)不溶性的(125)I标记的Fn,我们确定ASGP-R系统是否也能影响各种形式的Fn在肝脏基质中的保留。静脉注射后,(125)I-pFn、(125)I-aFn和(125)I-cFn迅速沉积到肝脏ECM中。虽然(125)I-pFn在24小时内从肝脏基质中缓慢丢失,但超过90%整合的(125)I-aFn和(125)I-cFn在4小时内被清除(P < 0.01)。静脉输注过量未标记的去唾液酸胎球蛋白以竞争性抑制肝脏ASGP-R,延迟了已经整合到肝脏ECM中的aFn和cFn的快速周转。在体外使用预先在体内用任何一种示踪形式的Fn预加载的肝切片测定,(125)I-aFn和(125)I-cFn在ECM中的保留也少于(125)I-pFn(P < 0.01)。肝脏ASGP-R似乎参与了肝脏ECM中aFn和cFn的周转,而一条与ASGP-R无关的内吞途径显然影响了整合到肝脏ECM中的正常pFn的清除,除非它在局部去唾液酸化。